UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 20, 2015
TetraLogic Pharmaceuticals Corporation
(Exact name of Registrant as specified in its charter)
Delaware |
|
001-36208 |
|
42-1604756 |
(State or Other Jurisdiction of Incorporation or Organization) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
343 Phoenixville Pike
Malvern, PA 19355
(610) 889-9900
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrants Principal
Executive
Offices)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 20, 2015, TetraLogic Pharmaceuticals Corporation (the Company) held its Annual Meeting of Stockholders. The following proposals were submitted by the Companys Board of Directors to a vote of the Companys stockholders and the final results of the voting on each proposal are noted below.
Proposal 1 Election of Directors
The stockholders elected the following individuals to serve as Class II directors for three-year terms until the 2018 annual meeting of stockholders and until each directors successor is elected and qualified:
Name |
|
Votes For |
|
Votes Withheld |
|
Broker |
|
Douglas E. Onsi |
|
9,644,551 |
|
999,801 |
|
7,186,098 |
|
Name |
|
Votes For |
|
Votes Withheld |
|
Broker |
|
Andrew Pecora, M.D. |
|
10,613,532 |
|
30,820 |
|
7,186,098 |
|
Proposal 2 Ratification of the selection of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2015
The stockholders ratified the appointment of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2015 as follows:
For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
|
17,798,056 |
|
1,764 |
|
30,630 |
|
|
|
Proposal 3 Approval of the flexible settlement feature with respect to the future potential conversions of the Companys 8% convertible senior notes
The stockholders approved the flexible settlement feature with respect to the future potential conversions of the Companys 8% convertible senior notes as follows:
For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
|
10,597,982 |
|
24,959 |
|
21,411 |
|
7,186,098 |
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 4, 2015 |
TetraLogic Pharmaceuticals Corporation | |
|
|
|
|
|
|
|
By: |
/s/ Richard L. Sherman |
|
|
Name: Richard L. Sherman |
|
|
Title: Senior Vice President, Strategic Transactions, General Counsel and Secretary |